Literature DB >> 15235580

ABO-incompatible bone marrow transplantation: a GITMO survey of current practice in Italy and comparison with the literature.

R Raimondi1, M Soli, T Lamparelli, A Bacigalupo, W Arcese, M Belloni, F Rodeghiero.   

Abstract

ABO incompatibility is not considered a contraindication for allogeneic haematopoietic stem cell transplantation (HSCT) despite its association with several immunohaematological complications. At present, there is no general agreement concerning the best methods to reduce these problems. To survey current practice related to ABO-incompatible HSCT in Italy, a questionnaire was sent to all GITMO centres. Specific questions were addressed for management in pretransplant, peritransplant and post transplant phases. A comparison was made with the experience reported in the literature. In all, 74% of GITMO centres answered the questionnaire. A high degree of heterogeneity concerning the pretransplant tests, methods to overcome infusion of ABO-incompatible marrow and post transplant transfusion policy and monitoring was evident. For many of these aspects the literature does not contain unanimous guidelines. The considerable degree of heterogeneity that reflects, at least partially, the lack of consensus in the literature demonstrates that ABO incompatibility is still an open issue in the setting of HSCT and that further studies are needed for a more rationale approach and for the production of evidence-based guidelines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15235580     DOI: 10.1038/sj.bmt.1704579

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

1.  Clinically significant adverse events after major ABO mismatch BMT.

Authors:  R S Nickel; E K Waller; M Qayed; K-Y Chiang
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

2.  Fully automated, clinical-grade bone marrow processing: a single-centre experience.

Authors:  Benedetta Mazzanti; Serena Urbani; Simone Dal Pozzo; Paola Bufano; Lara Ballerini; Alessia Gelli; Irene Sodi; Irene Donnini; Massimo Di Gioia; Stefano Guidi; Julien Camisani; Riccardo Saccardi
Journal:  Blood Transfus       Date:  2016-09-27       Impact factor: 3.443

3.  Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT.

Authors:  C K Brierley; T J Littlewood; A J Peniket; R Gregg; J Ward; A Clark; A Parker; R Malladi; P Medd
Journal:  Bone Marrow Transplant       Date:  2015-04-13       Impact factor: 5.483

4.  Immuno-hematological monitoring after allogeneic stem cell transplantation: a single-center, prospective study of 104 patients.

Authors:  Ursula La Rocca; Walter Barberi; Arianna Di Rocco; Gianluca Giovannetti; Alessia Neri; Isabella Santilio; Daniela Carmini; Luisa Quattrocchi; Maria Gozzer; Mahnaz Shafii Bafti; Roberto Ricci; Gabriella Girelli; Robin Foà; Anna Paola Iori; Serelina Coluzzi
Journal:  Blood Transfus       Date:  2022-04-19       Impact factor: 5.752

5.  Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.

Authors:  Georg Stussi; Jörg Halter; Eveline Bucheli; Piero V Valli; Lutz Seebach; Jürg Gmür; Alois Gratwohl; Urs Schanz; Jakob R Passweg; Jörg D Seebach
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

6.  Infusion hemolysis after pediatric major ABO-mismatched bone marrow transplant: Comparison of two red blood cell depletion techniques.

Authors:  Robert Sheppard Nickel; Muna Qayed; Diana Worthington-White; Sean R Stowell; Kuang-Yueh Chiang
Journal:  Pediatr Blood Cancer       Date:  2017-11-08       Impact factor: 3.838

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.